Search

Displaying results 381 - 390 of 1993 in total
  1. Drug

    RP-72

    go.drugbank.com/drugs/DB17156
    Investigational

    Synonyms: CXC chemokine receptor types 1 and 2 inhibitor RP72
  2. Drug

    Clotrimazole

    go.drugbank.com/drugs/DB00257
    ApprovedInvestigationalVet approved

    The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as

    Products: Gehwol med Foot, 1MED Clotrimazole 1% Antifungal Cream
  3. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

    Categories: Mitogen-activated protein kinase (MEK) inhibitors
  4. Drug

    Vixarelimab

    go.drugbank.com/drugs/DB16350
    Investigational

    Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).

    Synonyms: Immunoglobulin g (234-proline,303-glutamine), anti-(human oncostatin m receptor subunit .beta.) (human monoclonal kpl-716 .gamma.-chain), disulfide with human monoclonal kpl-716 .lambda.-chain, dimer
  5. Drug

    Stapokibart

    go.drugbank.com/drugs/DB18990
    Investigational

    Stapokibart is under investigation in clinical trial NCT06424470 (Study on the Treatment of Prurigo Nodularis With Stapokibart Injection).

    Synonyms: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
  6. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

    Categories: Mitogen-activated protein kinase (MEK) inhibitors
  7. Drug

    Domvanalimab

    go.drugbank.com/drugs/DB18848
    Investigational

    Domvanalimab is under investigation in clinical trial NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-small Cell Lung Cancer).

    Synonyms: Immunoglobulin g1 (236-alanine,237-alanine,de-c-terminal-lysine), anti-(human receptor tigit)(human-mus musculus monoclonal ab154 .gamma.1-chain), disulfide with human-mus musculus monoclonal ab154 .kappa
  8. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    This affects hemoglobin levels, and in patients with severe forms of this disease, long-term red cell transfusions are required for survival and the prevention of serious complications.

  9. Drug

    Substance P

    go.drugbank.com/drugs/DB19198
    Investigational

    Substance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).

    Synonyms: Arg-pro-lys-pro-gln-gln-phe-phe-gly-leu-met-nh2
  10. Drug

    Capsaicin

    go.drugbank.com/drugs/DB06774
    ApprovedInvestigational

    The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

    Mixtures: Med O-3 Bio-, Medi-derm RxProducts: Red Hot, Red hot